Accession Number

Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.5,8

Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Structure
Protein Chemical Formula
Not Available
Protein Average Weight
148000.0 Da
>Amino acid sequence for pertuzumab light chain 
>Amino acid sequence for pertuzumab heavy chain 
Download FASTA Format
  • 2C4 Antibody
  • MOAB 2C4
  • Monoclonal Antibody 2C4
  • Pertuzumab
  • rhuMAb-2C4
External IDs
  • R1273
  • RG-1273



Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.6 It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen6 and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.6

Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - in the treatment of HER2-positive breast cancers in adults.4

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More

Pertuzumab exerts its antineoplastic effects by binding to and inhibiting the activity of HER2, an oncogene that has been implicated in the formation of numerous cancers.6 As with other therapeutic monoclonal antibodies, pertuzumab has a relatively long duration of action necessitating dosing every 3 weeks.6 Drugs that block HER2 activity, including pertuzumab, have been implicated in the development of cardiotoxicity (specifically left ventricular dysfunction) - a baseline assessment of left ventricular ejection fraction (LVEF) should be conducted prior to beginning therapy with pertuzumab and at regular intervals throughout therapy to ensure LVEF remains within normal limits. Consider indefinite suspension of therapy if LVEF declines and does not improve.6

Mechanism of action

Human epidermal growth factor receptor-2 (HER2) is a tyrosine kinase receptor that plays an integral role in cell proliferation, differentiation, and survival. HER2 becomes active following dimerization with another HER2 receptor, another member of the HER protein family (e.g. HER3), or with a ligand - this dimer then phosphorylates and activates numerous intracellular signaling proteins, initiating signal transduction via pathways that include the Ras/mitogen-activated protein kinase pathway, the phosphatidylinositol 3' kinase (PI3K)/Akt pathway, and then Janus kinases/signal transducer and activator transcription pathway.2 HER2 is also a known oncogene - it is overexpressed or gene-amplified (i.e. HER2-positive) in approximately 20% of breast cancers and these cancers carry a generally poorer prognosis than HER2-negative breast cancers.2

Pertuzumab targets the extracellular dimerization domain (subdomain II) of HER2, thereby inhibiting ligand-initiated intracellular signaling via the MAP kinase and PI3K pathways. Inhibition of these pathways results in inhibition of cell growth and the initiation of apoptosis, respectively.5 Pertuzumab also appears to mediate antibody-dependent cell-mediated cytotoxicity.5

AReceptor tyrosine-protein kinase erbB-2

Intravenously administered pertuzumab, given as a loading dose of 840mg followed by a maintenance dose of 420mg every 3 weeks, reaches steady-state concentration following the first maintenance dose.6 In its subcutaneous formulation, in combination with [hylauronidase], the absolute bioavailability of pertuzumab is approximately 0.7 and the median Tmax is 4 days.7 This subcutaneous formulation leverages the benefits of co-administration with hyaluronidase - this enzyme breaks down hylauronic acid, thereby decreasing the viscosity of the extracellular matrix (ECM) and allowing for greater bioavailability with subcutaneous administration.7

Volume of distribution

The average steady-state volume of distribution following intravenous administration is 3.53 - 7.5 L.6

Protein binding
Not Available

The metabolism of pertuzumab has not been studied directly. Monoclonal antibodies are typically subject to catabolism to smaller peptides and proteins prior to elimination.6

Route of elimination
Not Available

The median half-life of pertuzumab was determined to be 18 days based on a population pharmacokinetic analysis.5


The median clearance of pertuzumab was determined to be 0.24 L/day based on a population pharmacokinetic analysis.5

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More

There are no data regarding overdose of pertuzumab. Single doses higher than 25 mg/kg have not been tested.6 Symptoms of overdose are likely to be consistent with pertuzumab's adverse effect profile, and may therefore involve significant diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and/or peripheral neuropathy.5 Pertuzumab has been associated with the development of left ventricular dysfunction (i.e. cardiotoxicity) that may be exacerbated in instances of overdose.5

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Pertuzumab.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pertuzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Pertuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pertuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Pertuzumab is combined with Alirocumab.
AmsacrineThe risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Pertuzumab.
AnastrozoleThe risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Pertuzumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Pertuzumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Pertuzumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Pertuzumab is combined with Antilymphocyte immunoglobulin (horse).
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.


International/Other Brands
Omnitarg / Perjeta
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
PerjetaInjection, solution, concentrate420 mgIntravenousRoche Registration Gmb H2013-03-04Not applicableEU flag
PerjetaSolution420 mgIntravenousHoffmann La Roche2013-05-08Not applicableCanada flag
PerjetaInjection, solution, concentrate30 mg/1mLIntravenousGenentech, Inc.2012-06-08Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Perjeta-herceptinPertuzumab (420 mg) + Trastuzumab (440 mg)Kit; Powder, for solution; SolutionIntravenousHoffmann La Roche2013-05-09Not applicableCanada flag
PhesgoPertuzumab (1200 mg/15mL) + Hyaluronidase (human recombinant) (2000 U/15mL) + Trastuzumab (600 mg/15mL)Injection, solutionSubcutaneousGenentech, Inc.2020-06-29Not applicableUS flag
PhesgoPertuzumab (600 mg/10mL) + Hyaluronidase (human recombinant) (2000 U/10mL) + Trastuzumab (600 mg/10mL)Injection, solutionSubcutaneousGenentech, Inc.2020-06-29Not applicableUS flag


ATC Codes
L01XC13 — Pertuzumab
Drug Categories
Chemical TaxonomyProvided by Classyfire
Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

CAS number


Synthesis Reference

Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX: Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006 Jun;55(6):717-27. doi: 10.1007/s00262-005-0058-x. Epub 2005 Sep 3.

General References
  1. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX: Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006 Jun;55(6):717-27. doi: 10.1007/s00262-005-0058-x. Epub 2005 Sep 3. [PubMed:16151804]
  2. Malenfant SJ, Eckmann KR, Barnett CM: Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer. Pharmacotherapy. 2014 Jan;34(1):60-71. doi: 10.1002/phar.1338. Epub 2013 Aug 5. [PubMed:23918291]
  3. Pertuzumab protein sequence [Link]
  4. FDA News Release: FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional [Link]
  5. FDA Approved Drug Products: Perjeta (pertuzumab) for intravenous injection [Link]
  6. Health Canada Product Monograph: Perjeta (pertuzumab) for intravenous injection [Link]
  7. FDA Approved Drug Products: Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) for subcutaneous injection [Link]
  8. FDA Drug Approvals: FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer [Link]
PubChem Substance
RxList Drug Page Drug Page
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (362 KB)

Clinical Trials

Clinical Trials
4CompletedDiagnosticBreast Cancer1
4CompletedTreatmentBreast Cancer1
3Active Not RecruitingTreatmentBreast Cancer5
3Active Not RecruitingTreatmentBreast Cancer / HER2 Positive1
3Active Not RecruitingTreatmentEarly Breast Cancer1
3Active Not RecruitingTreatmentHER2 Positive Breast Carcinoma / Hormone Receptor Positive Breast Adenocarcinoma / Stage IB Breast Cancer AJCC v7 / Stage IIA Breast Cancer AJCC v6 and v7 / Stage IIB Breast Cancer AJCC v6 and v7 / Stage IIIA Breast Cancer AJCC v7 / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer AJCC v71
3Active Not RecruitingTreatmentHER2-positive Locally Advanced or Metastatic Breast Cancer1
3CompletedTreatmentBreast Cancer4
3CompletedTreatmentHER2 Positive Breast Cancers / Inflammatory Breast Cancer (IBC) / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
3CompletedTreatmentMalignant Neoplasm of Stomach1


Not Available
Not Available
Dosage Forms
InjectionIntravenous30 MG/ML
Injection, solution, concentrateIntravenous30 mg/1mL
Injection, solution, concentrateIntravenous420 mg/14ml
Injection, solution, concentrateIntravenous420 mg
Injection, solution, concentrateIntravenous; Parenteral420 MG
SolutionIntravenous420 mg
Injection, solution, concentrateParenteral420 mcg/14mL
Solution, concentrateIntravenous420 mg
Kit; powder, for solution; solutionIntravenous
Injection, solutionSubcutaneous
Not Available
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
CA2376596No2009-10-062020-06-23Canada flag
CA2579861No2012-12-182025-10-19Canada flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
Not Available


Pharmacological action
General Function
Transmembrane signaling receptor activity
Specific Function
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, alt...
Gene Name
Uniprot ID
Uniprot Name
Receptor tyrosine-protein kinase erbB-2
Molecular Weight
137909.27 Da
  1. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004 Apr;5(4):317-28. [PubMed:15093539]
  2. FDA Approved Drug Products: Perjeta (pertuzumab) for intravenous injection [Link]

Drug created on March 19, 2008 10:27 / Updated on January 25, 2021 22:38